Alnylam Pharmaceuticals Prices Public Offering of Common Stock
CAMBRIDGE, Mass. -- January 15, 2013
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), a leading RNAi therapeutics
company, today announced the pricing of an underwritten registered public
offering of 8,000,000 shares of its common stock at a public offering price of
$20.13 per share. All of the shares in the offering are to be sold by Alnylam.
The offering is expected to close on or about January 22, 2013, subject to the
satisfaction of customary closing conditions.
J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC are acting as joint
book-running managers and representatives of the underwriters for the
offering. Deutsche Bank Securities Inc., Piper Jaffray & Co., Leerink Swann
LLC, Needham & Company, LLC and JMP Securities LLC are acting as co-managers
for the offering. Alnylam has granted the underwriters a 30-day option to
purchase up to 1,200,000 shares to cover overallotments, if any.
The securities described above are being offered by Alnylam pursuant to an
automatically effective shelf registration statement that Alnylam previously
filed with the Securities and Exchange Commission (SEC).
This press release shall not constitute an offer to sell or the solicitation
of an offer to buy any securities nor shall there be any sale of these
securities in any state in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the securities laws of
such state. A preliminary prospectus supplement related to the offering has
been filed with the SEC. Before you invest, you should read the prospectus and
the related prospectus supplement and any other document Alnylam has filed
with the SEC for more complete information about Alnylam and this offering.
You may get these documents for free by visiting EDGAR on the SEC Website at
www.sec.gov. Alternatively, copies of the prospectus and the prospectus
supplements relating to this offering may be obtained by contacting J.P.
Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island
Avenue, Edgewood, New York 11717 (telephone: 866-803-9204); or Morgan Stanley
& Co. LLC, Attn: Prospectus Department, 180 Varick Street, 2nd Floor, New
York, NY 10014 (telephone: 866-718-1649, email: email@example.com).
About Alnylam Pharmaceuticals
Alnylam is a biopharmaceutical company developing novel therapeutics based on
RNA interference, or RNAi. The company is leading the translation of RNAi as a
new class of innovative medicines with a core focus on RNAi therapeutics for
the treatment of genetically defined diseases, including ALN-TTR for the
treatment of transthyretin-mediated amyloidosis (ATTR), ALN-AT3 for the
treatment of hemophilia and rare bleeding disorders (RBD), ALN-AS1 for the
treatment of acute intermittent porphyria, ALN-PCS for the treatment of severe
hypercholesterolemia, and ALN-TMP for the treatment of hemoglobinopathies. As
part of its “Alnylam 5x15™” strategy, the company expects to have five RNAi
therapeutic products for genetically defined diseases in clinical development,
including programs in advanced stages, on its own or with a partner by the end
of 2015. Alnylam has additional partnered programs in clinical or development
stages, including ALN-RSV01 for the treatment of respiratory syncytial virus
(RSV) infection and ALN-VSP for the treatment of liver cancers. The company’s
leadership position on RNAi therapeutics and intellectual property have
enabled it to form major alliances with leading companies including Merck,
Medtronic, Novartis, Biogen Idec, Roche, Takeda, Kyowa Hakko Kirin, Cubist,
Ascletis, Monsanto and Genzyme. In addition, Alnylam holds a significant
equity position in Regulus Therapeutics Inc., a company focused on discovery,
development, and commercialization of microRNA therapeutics. Alnylam has also
formed Alnylam Biotherapeutics, a division of the company focused on the
development of RNAi technologies for applications in biologics manufacturing,
including recombinant proteins and monoclonal antibodies. Alnylam’s VaxiRNA™
platform applies RNAi technology to improve the manufacturing processes for
vaccines; GlaxoSmithKline is a collaborator in this effort. Alnylam scientists
and collaborators have published their research on RNAi therapeutics in over
100 peer-reviewed papers, including many in the world’s top scientific
journals such as Nature, Nature Medicine, Nature Biotechnology, and Cell.
Founded in 2002, Alnylam maintains headquarters in Cambridge, Massachusetts.
Alnylam Forward-Looking Statements
Statements in this release concerning Alnylam’s future expectations, plans and
prospects constitute forward-looking statements for the purposes of the safe
harbor provisions under The Private Securities Litigation Reform Act of 1995.
Actual results may differ materially from those indicated by these
forward-looking statements as a result of various important factors, including
risks related to fluctuations in our stock price, those associated with market
conditions and the satisfaction of customary closing conditions related to the
proposed offering, as well as those risks more fully discussed in the “Risk
Factors” filed with Alnylam’s current report on Form 8-K filed with the SEC on
January 14, 2013 and in other filings that Alnylam makes with the SEC. There
can be no assurance that Alnylam will be able to complete the proposed public
offering on the anticipated terms, or at all. You should not place undue
reliance on these forward-looking statements. In addition, any forward-looking
statements represent Alnylam’s views only as of today and should not be relied
upon as representing Alnylam’s views as of any subsequent date. Alnylam
disclaims any obligation to update any forward-looking statements.
Alnylam Pharmaceuticals, Inc.
Cynthia Clayton, 617-551-8207
Vice President, Investor Relations and Corporate Communications
Michael P. Mason, 617-551-8327
Vice President, Finance and Treasurer
Press spacebar to pause and continue. Press esc to stop.